|
Home
|
E-Submission
|
Sitemap
|
Editorial Office
|
Aims and Scope
About the Journal
Editorial Board
Open Access
Best Reviewer Awardees
Article Processing Charge
Editorial Office
Instructions for Authors
Research and Publication Ethics
Checklist
E-Submission
Copyright Transfer Agreement
All issues
Accepted Articles
Epub Ahead-of Print Articles
Current Issue
Most Read Articles
Most Cited Articles
Cancer Research and Treatment
Search
Author Index
Cancer Research and Treatment
Search
> Browse Articles > Search
Sarcoma
Comprehensive Molecular Characterization of Soft Tissue Sarcoma for Prediction of Pazopanib-Based Treatment Response
Jung Yong Hong, Hee Jin Cho, Kum-Hee Yun, Young Han Lee, Seung Hyun Kim, Wooyeol Baek, Sang Kyum Kim, Yurimi Lee, Yoon-La Choi, Minsuk Kwon, Hyo Song Kim, Jeeyun Lee
Cancer Res Treat.
2023;55(2):671-683. Published online September 27, 2022 DOI:
https://doi.org/10.4143/crt.2022.251
Web of Science 3
Crossref 3
Gastrointestinal cancer
Molecular and Immune Profiling of Syngeneic Mouse Models Predict Response to
Immune Checkpoint Inhibitor
s in Gastric Cancer
Dagyeong Lee, Junyong Choi, Hye Jeong Oh, In-Hye Ham, Sung Hak Lee, Sachiyo Nomura, Sang-Uk Han, Hoon Hur
Cancer Res Treat.
2023;55(1):167-178. Published online May 20, 2022 DOI:
https://doi.org/10.4143/crt.2022.094
Web of Science 3
Crossref 3
Gynecologic cancer
Frequency of Mismatch Repair Deficiency/High Microsatellite Instability and Its Role as a Predictive Biomarker of Response to
Immune Checkpoint Inhibitor
s in Gynecologic Cancers
Joseph J. Noh, Min Kyu Kim, Min Chul Choi, Jeong-Won Lee, Hyun Park, Sang Geun Jung, Won Duk Joo, Seung Hun Song, Chan Lee
Cancer Res Treat.
2022;54(4):1200-1208. Published online December 13, 2021 DOI:
https://doi.org/10.4143/crt.2021.828
Web of Science 9
Crossref 8
Gastrointestinal cancer
Histopathologic and Molecular Biomarkers of PD-1/PD-L1 Inhibitor Treatment Response among Patients with Microsatellite Instability‒High Colon Cancer
Jaewon Hyung, Eun Jeong Cho, Jihun Kim, Jwa Hoon Kim, Jeong Eun Kim, Yong Sang Hong, Tae Won Kim, Chang Ohk Sung, Sun Young Kim
Cancer Res Treat.
2022;54(4):1175-1190. Published online January 12, 2022 DOI:
https://doi.org/10.4143/crt.2021.1133
Web of Science 6
Crossref 7
Lung and Thoracic cancer
Clinical Efficacy of
Immune Checkpoint Inhibitor
s in Non–Small Cell Lung Cancer Patients with Liver Metastases: A Network Meta-Analysis of Nine Randomized Controlled Trials
Qing Yin, Longguo Dai, Ruizhu Sun, Ping Ke, Liya Liu, Bo Jiang
Cancer Res Treat.
2022;54(3):803-816. Published online October 25, 2021 DOI:
https://doi.org/10.4143/crt.2021.764
Web of Science 4
Crossref 5
Histone Deacetylase as a Valuable Predictive Biomarker and Therapeutic Target in Immunotherapy for Non-Small Cell Lung Cancer
Hyun-Seock Shin, Juwhan Choi, Jinhwan Lee, Sung Yong Lee
Cancer Res Treat.
2022;54(2):458-468. Published online September 10, 2021 DOI:
https://doi.org/10.4143/crt.2021.425
Web of Science 6
Crossref 8
Comparison of the Predictive Power of a Combination versus Individual Biomarker Testing in Non–Small Cell Lung Cancer Patients Treated with
Immune Checkpoint Inhibitor
s
Hyojin Kim, Hyun Jung Kwon, Eun Sun Kim, Soohyeon Kwon, Kyoung Jin Suh, Se Hyun Kim, Yu Jung Kim, Jong Seok Lee, Jin-Haeng Chung
Cancer Res Treat.
2022;54(2):424-433. Published online July 7, 2021 DOI:
https://doi.org/10.4143/crt.2021.583
Web of Science 10
Crossref 5
General
Engineering a High-Affinity PD-1 Peptide for Optimized Immune Cell-Mediated Tumor Therapy
Yilei Chen, Hongxing Huang, Yin Liu, Zhanghao Wang, Lili Wang, Quanxiao Wang, Yan Zhang, Hua Wang
Cancer Res Treat.
2022;54(2):362-374. Published online August 3, 2021 DOI:
https://doi.org/10.4143/crt.2021.424
Web of Science 4
Crossref 4
Rare Cancer
Clinical Experience of Male Primary Choriocarcinoma at the Samsung Medical Center
Young Sok Ji, Se Hoon Park
Cancer Res Treat.
2021;53(3):874-880. Published online December 7, 2020 DOI:
https://doi.org/10.4143/crt.2020.1066
Web of Science 8
Crossref 7
Immunotherapy
The Pattern of Time to Onset and Resolution of Immune-Related Adverse Events Caused by
Immune Checkpoint Inhibitor
s in Cancer: A Pooled Analysis of 23 Clinical Trials and 8,436 Patients
Si-Qi Tang, Ling-Long Tang, Yan-Ping Mao, Wen-Fei Li, Lei Chen, Yuan Zhang, Ying Guo, Qing Liu, Ying Sun, Cheng Xu, Jun Ma
Cancer Res Treat.
2021;53(2):339-354. Published online November 6, 2020 DOI:
https://doi.org/10.4143/crt.2020.790
Web of Science 56
Crossref 63
Lung cancer
Sequential Treatment with an
Immune Checkpoint Inhibitor
Followed by a Small-Molecule Targeted Agent Increases Drug-Induced Pneumonitis
Jongheon Jung, Hyae Young Kim, Dong-Gil Kim, Seog Yun Park, A Ra Ko, Ji-Youn Han, Heung Tae Kim, Jin Soo Lee, Youngjoo Lee
Cancer Res Treat.
2021;53(1):77-86. Published online August 6, 2020 DOI:
https://doi.org/10.4143/crt.2020.543
Web of Science 8
Crossref 8
Association between PD-L1 and HPV Status and the Prognostic Value of PD-L1 in Oropharyngeal Squamous Cell Carcinoma
Hae Su Kim, Ji Yun Lee, Sung Hee Lim, Keunchil Park, Jong-Mu Sun, Young Hyeh Ko, Chung-Hwan Baek, Young-ik Son, Han Sin Jeong, Yong Chan Ahn, Min-Young Lee, Mineui Hong, Myung-Ju Ahn
Cancer Res Treat.
2016;48(2):527-536. Published online September 15, 2015 DOI:
https://doi.org/10.4143/crt.2015.249
Web of Science 101
Crossref 96
1
Journal Impact Factor 4.6